A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report

INTRODUCTION: The mRNA vaccine, mRNA-1273/TAK-919, encodes the prefusion-stabilised spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report interim results of the first study evaluating safety and immunogenicity of mRNA-1273 in healthy Japanese participants. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Taisei, Murakami, Kyoko, Sugiura, Kenkichi, Sakui, Sho, Philip Schuring, Ron, Mori, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824367/
https://www.ncbi.nlm.nih.gov/pubmed/35177302
http://dx.doi.org/10.1016/j.vaccine.2022.02.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824367/
https://www.ncbi.nlm.nih.gov/pubmed/35177302
http://dx.doi.org/10.1016/j.vaccine.2022.02.030

Ejemplares similares